Тяжелая эозинофильная астма: терапевтический потенциал Реслизумаба
https://doi.org/10.21518/2079-701X-2018-15-70-75
Аннотация
В обзоре рассматриваются проблемы, связанные с лечением больных с тяжелой резистентной к терапии бронхиальной астмой: распространенность, социально-экономический ущерб, влияние на качество жизни. Детально обсуждается фенотип бронхиальной астмы с эозинофильным воспалением, частота встречаемости, клинические особенности и современные подходы к терапии, включая применение препарата моноклональных антител против интерлейкина-5 реслизумаба.
Об авторе
Р. С. Фассахов
Институт фундаментальной медицины и биологии Казанского (Приволжского) федерального университета
Россия
Фассахов Рустем Салахович – доктор медицинских наук, профессор, кафедра фундаментальных основ клинической медицины
Россия
Фассахов Рустем Салахович – доктор медицинских наук, профессор, кафедра фундаментальных основ клинической медицины
Список литературы
1. Global Initiative for Asthma, https://ginasthma.org.
2. Национальные клинические рекомендации «Бронхиальная астма», М., 2017.
3. Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология, 2011, (6): 87-93.
4. Braido F, Brusselle G, Guastalla D, et al. Determinants and impact of suboptimal asthma control in Europe: The INTERNATIONAL CROSS-SECTIONAL AND LONGITUDINAL ASSESSMENT ON ASTHMA CONTROL (LIAISON) study. Respiratory Research, 2016, 17: 51.
5. Price D, Fletcher M, and van der Molen T Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med, 2014, 24: 14009. doi: 10.1038/npjpcrm.2014.9.
6. Lockey R. Asthma Phenotypes: An Approach to the Diagnosis and Treatment of Asthma. J Allergy Clin Immunol In Practice, 2014, 2(6): 682–685.
7. Moore WC, Meyers DA, Wenzel SE et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med, 2010, 181: 315–323.
8. de Groot J, Storm H, Amelink M, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Research, 2016, 2: 001002015. doi: 10.1183/23120541.00100-2015.
9. Miranda C, Busacker A, Balzar S, et al. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol, 2004, 113(1): 101-108.
10. Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J, 2017, 49: 1700634. doi: 10.1183/13993003.00634-2017.
11. Woodruff P, Khashayar R, Lazarus S et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. 2001, 108(5): 753–758.
12. Porsbjerg C, Lund T, Pedersen L, Backer V. Inflammatory subtypes in asthma are related to airway hyperresponsiveness to mannitol and exhaled NO. J Asthma, 2009, 46(6): 606-612.
13. Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med, 2015, 3: 849–58.
14. Denlinger LC, Phillips BR, Ramratnam S, et al. Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations. Am J Respir Crit Care Med, 2017, 195: 302–13.
15. Blakey JD, Price DB, Pizzichini E, et al. Identifying risk of future asthma attacks usingUK medical record data: a respiratory effectiveness group initiative. J Allergy ClinImmunol Pract, 2017, 5: 1015–24.
16. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J, 2014, 43(2): 343– 73.
17. Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a reviewof the prevalence, disease burden and options for treatment. Respir Med, 2006, 100(7): 1139–51.
18. Kerkhof M, Tran TN, Soriano JB, et al. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. Thorax, 2018, 73(2): 116– 124.
19. Husereau D, Goodfield J, Leigh Ri, et al. Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. Allergy Asthma Clin Immunol, 2018, 14: 15.
20. Casciano J, Krishnan J, Small M, et al. Burden of asthma with elevated blood eosinophil levels- BMC Pulmonary Medicine, 2016, 16: 100 doi. org/10.1186/s12890-016-0263-8.
21. Mäkelä M, Christensen HN, Karlsson A, et al. Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland. Eur Clin Respir J, 2018, 5(1): 1458560. doi: 10.1080/20018525.2018.1458560.
22. Ilmarinen P, Tuomisto LE, Niemelä O, et al. Prevalence of patients eligible for anti-IL-5 treatment in a cohort of adult-onset asthma. The Jour nal of Allergy and Clinical Immunology: In Practice, 2018, doi: 10.1016/j.jaip.2018.05.032.
23. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol, 2015, 16: 45–56.
24. Pelaia G, Vatrella A, Busceti MT, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm, 2015, 2015: 879783.
25. Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med, 2013, 19: 977– 979.
26. Walsh GM. Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma. Biologics, 2013, 7: 7–11.
27. Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung, 1999, 49: 779–790.
28. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med, 2015, 3: 355–366.
29. Castro M, Mathur S Hargreave F, Boulet LP, Xie F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebocontrolled study. Am J Respir Crit Care Med, 2011, 184: 1125–1132.
30. Murphy K, Jacobs J, Bjermer L, et al. Long-term safety and efficacy of reslizumab in patients with inadequately controlled, moderate-tosevere asthma and elevated blood eosinophil counts: an open-label extension study. Presented at the American Thoracic Society (ATS) International Conference, 15–20 May 2015.
31. Denver, CO, USA. Poster #1025, Corren J, Weinstein S, Janka L, et al. A randomized Phase 3 study of reslizumab efficacy in relation to blood eosinophil levels in patients with moderate to severe asthma. Presented at the European Respiratory Society (ERS) International Congress, 6–10 September 2014, Munich, Germany. Oral 4673.
32. Bjermer L, Lemiere C, Maspero J, et al. A randomized Phase 3 study of the efficacy and safety of reslizumab in subjects with asthma with elevated eosinophils. Presented at the European Respiratory Society (ERS) International Congress, 6–10 September 2014, Munich, Germany. Poster P4375.
33. Bjermer L, Lemiere C, Maspero J, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 Study. Chest, 2016, 150(4): 789798.
34. Cazzola M, Matera M, Levi-Schaffer F, Rogliani P. Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab. Expert Opinion on Drug Safety, 2018. doi: 10.1080/14740338.2018.1446940.
Рецензия
Для цитирования:
Фассахов РС. Тяжелая эозинофильная астма: терапевтический потенциал Реслизумаба. Медицинский Совет. 2018;(15):70-75. https://doi.org/10.21518/2079-701X-2018-15-70-75
For citation:
Fassakhov RS. Severe eosinophilic asthma: therapeutic potential of Reslizumab. Meditsinskiy sovet = Medical Council. 2018;(15):70-75. (In Russ.) https://doi.org/10.21518/2079-701X-2018-15-70-75
Просмотров:
1179
Послать статью по эл. почте 